Alzheimer’s Screening: A New Era of Early Detection

Why Early Screening Matters

Alzheimer’s disease is a progressive brain disorder that affects memory, thinking, and behavior. Detecting it early can make a significant difference. Early diagnosis allows individuals and families to plan for the future, access treatments that may slow progression, and participate in clinical trials that could shape the future of care.

What Is Alzheimer’s Screening?

Alzheimer’s screening involves a combination of tools and tests that help identify signs of cognitive decline and determine whether Alzheimer’s or another condition may be the cause. These may include:

Cognitive assessments: Simple memory and thinking tests administered during a routine check-up.
Blood tests: Innovations like the pTau217 blood biomarker test can detect Alzheimer ’s-related changes in the brain with high accuracy.
Brain imaging: Doctors may use MRI or PET scans to rule out other causes or confirm a diagnosis.
Genetic testing: In some cases, healthcare professionals may use tests, such as the APOE gene test, to assess risk.

Advanced Testing Options at Our Laboratory

We offer a comprehensive suite of blood-based cerebrospinal fluid (CSF) and genetic tests to support early and accurate detection of Alzheimer’s disease.

Blood-Based Biomarkers

These tests are less invasive and increasingly accessible:

pTau-217/Beta Amyloid 42 Ratio: A groundbreaking test launched nationwide by Labcorp. Offers results comparable to PET imaging and CSF testing.
Phosphorylated Tau 217 (pTau-217), Plasma: Detects amyloid pathology and supports monitoring of patients on anti-amyloid therapies.
Beta Amyloid 42/40 Ratio, Plasma: Indicates amyloid buildup in the brain.
Glial Fibrillary Acidic Protein (GFAP): A marker of brain inflammation used alongside amyloid markers.
Neurofilament Light Chain (NfL), Plasma: Reflects the degree of neurodegeneration.
Phosphorylated Tau 181 (pTau-181), Plasma: Helps distinguish Alzheimer’s from other dementias.
ATN Profile: A comprehensive blood-based panel combining Amyloid, Tau, and Neurodegeneration markers.

Cerebrospinal Fluid (CSF) Biomarkers

For a more detailed analysis:

Alzheimer's Disease Evaluation Profile, CSF: Measures Beta-Amyloid (1-42), total Tau, and Phospho-Tau (181P).
Beta Amyloid 42/40 Ratio, CSF: Correlates with disease progression and PET imaging.

Genetic Testing

For assessing inherited risk:

APOE Alzheimer’s Risk Test: Identifies the APOE-4 variant linked to late-onset Alzheimer’s.
Early-Onset Alzheimer’s NGS Diagnostic Test: Uses next-generation sequencing to detect mutations in APP, PSEN1, and PSEN2 genes.

Who Should Consider Screening?

You may benefit from screening if you:

Are over age 65
Notice memory or thinking changes
Have a family history of Alzheimer’s
Are interested in clinical trials or early intervention

Innovating for the Future

We are proud to support innovative diagnostics that enhance accessibility to early detection. Our work alongside industry leaders and potential alliances with forward-thinking organizations demonstrates our dedication to advancing Alzheimer’s care.

Talk with your healthcare provider to determine if Alzheimer’s screening is appropriate for you, as early detection can significantly influence the course of treatment.